Anti-Tet2 antibody [CL6873] (ab243323)
Key features and details
- Mouse monoclonal [CL6873] to Tet2
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG2b
Overview
-
Product name
Anti-Tet2 antibody [CL6873]
See all Tet2 primary antibodies -
Description
Mouse monoclonal [CL6873] to Tet2 -
Host species
Mouse -
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human Tet2 aa 900-1000.
Database link: Q6N021 -
Positive control
- IHC-P: Human placenta, uterine cervix and tonsil tissues. WB: HL-60 cell lysate. ICC/IF: U-2 OS cells.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 40% Glycerol, PBS -
Concentration information loading...
-
Purity
Protein A purified -
Purification notes
Purified from TCS. -
Clonality
Monoclonal -
Clone number
CL6873 -
Isotype
IgG2b -
Research areas
Associated products
-
Compatible Secondaries
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab243323 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
Use a concentration of 1 µg/ml. Predicted molecular weight: 224 kDa.
|
IHC-P | (2) |
1/20 - 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
ICC/IF | (1) |
Use a concentration of 2 - 10 µg/ml.
Fixation/Permeabilization: PFA/Triton X-100 |
Notes |
---|
WB
Use a concentration of 1 µg/ml. Predicted molecular weight: 224 kDa. |
IHC-P
1/20 - 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ICC/IF
Use a concentration of 2 - 10 µg/ml. Fixation/Permeabilization: PFA/Triton X-100 |
Target
-
Function
Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. -
Tissue specificity
Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes. -
Involvement in disease
Note=TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.
Defects in TET2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
Note=TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen.
Note=TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. -
Sequence similarities
Belongs to the TET family. - Information by UniProt
-
Database links
- Entrez Gene: 54790 Human
- Omim: 612839 Human
- SwissProt: Q6N021 Human
- Unigene: 367639 Human
-
Alternative names
- FLJ20032 antibody
- KIAA1546 antibody
- MDS antibody
see all
Images
-
PFA-fixed, Triton X-100 permeabilized U-2 OS (human bone osteosarcoma epithelial cell line) cells stained for Tet2 (green) using ab243323 at 10 µg/ml in ICC/IF. Microtubules visualized in red.
-
Paraffin-embedded human uterine cervix tissue stained for Tet2 using ab243323 at 1/50 dilution in immunohistochemical analysis.
-
Paraffin-embedded human placenta tissue stained for Tet2 using ab243323 at 1/50 dilution in immunohistochemical analysis.
-
Paraffin-embedded human tonsil tissue stained for Tet2 using ab243323 at 1/50 dilution in immunohistochemical analysis.
-
Paraffin-embedded human pancreas tissue stained for Tet2 using ab243323 at 1/50 dilution in immunohistochemical analysis. Negative staining.
-
Anti-Tet2 antibody [CL6873] (ab243323) at 1 µg/ml + HL-60 (human promyelocytic leukemia cell line) cell lysate
Predicted band size: 224 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab243323 has been referenced in 3 publications.
- Kong FC et al. A novel epigenetic marker, Ten-eleven translocation family member 2 (TET2), is identified in the intractable epileptic brain and regulates ATP binding cassette subfamily B member 1 (ABCB1) in the blood-brain barrier. Bioengineered 13:6638-6649 (2022). PubMed: 35235761
- Zhang B et al. Circ_0084615 is an oncogenic circular RNA in colorectal cancer and promotes DNMT3A expression via repressing miR-599. Pathol Res Pract 224:153494 (2021). PubMed: 34091391
- Xu H et al. GATA6-AS1 inhibits ovarian cancer cell proliferation and migratory and invasive abilities by sponging miR-19a-5p and upregulating TET2. Oncol Lett 22:718 (2021). PubMed: 34429758